ClinicalTrials.gg
CompletedNCT00920426Updated Dec 6, 2017Results posted

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

A Phase 2 interventional study of GSK1265744 30mg and Placebo in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo.

The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is needed after Part 1, about 6 people will take part in Part 2 of the study receiving dose B.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • HIV
  • naive
  • Phase II
  • integrase inhibitor
  • GSK1265744
  • newly diagnosed
  • pharmacokinetics
  • AIDS
  • integrase
  • HIV Infections
  • Treatment naive
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 9 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  • Male or female between 18 and 65 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of non-, defined as:
  • Pre-menopausal females with a documented bilateral oophorectomy, tubal ligation or hysterectomy; or
  • defined as 12 months of spontaneous amenorrhea. A follicle stimulating hormone level will be performed to confirm post-menopausal status. For this study, FSH levels > 40 MlU/ml and estradiol \< 40 pg/ml (\<140 pmol/L) is confirmatory.
  • Male subjects must agree to use one of the methods listed in Section 8.1. This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of study medication.
  • greater than or equal to 200 cells/mm3 and plasma -1 RNA greater than or equal to 5000 copies/mL at Screening.
  • No current antiretroviral therapy and have not received any in the 12 weeks prior to first dose.
  • For subjects who have received antiretroviral treatment in the past, adequate treatment options to construct HAART therapy with at least 3 active antiretrovirals for Optimized Therapy, as selected by the Investigator.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • A positive screening surface antigen; positive screening virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) on subsequent testing. If the hepatitis C antibody is positive but the HCV RNA is undetectable, the subject may be included in the study.
  • and ALT > 3ULN at Screening. A single repeat is allowed for eligibility determination.
  • Inadequate renal function at Screening, defined as either a serum creatinine >1.5 mg/dL or a calculated (CrCl) ≤ 50 mL/min. A single repeat serum creatinine is allowed to determine eligibility.
  • Any acute laboratory abnormality at screening which, in the opinion of the investigator, should preclude the subject's participation in the study of an compound. Any grade 4 laboratory abnormality at screening, with the exception of CPK, will exclude a subject from study participation unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat is allowed for eligibility determination.
  • A positive drug screen at screening and baseline. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine or PCP.
  • History of regular alcohol consumption, defined as an average weekly intake of >14 drinks for males or >7 drinks for females, within 6 months of Screening.

Note: One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.

  • Any condition (including alcohol or drug abuse) which, in the opinion of the investigator, could interfere with the subject's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the subject.
  • Prior treatment with an integrase inhibitor (greater than or equal to 1 dose).
  • Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 30 days of study drug administration or anticipated need for such treatment within the study.
  • Treatment with immunomodulating agents (such as systemic , interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of study drug administration.
  • Treatment with any vaccine within 30 days prior to receiving study medication.
  • An active Center for Disease Control and Prevention (CDC) Category C disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Lactating females.
  • Use of multivitamins or antacids within 24 hours prior to the first dose of investigational product.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.

Note: Study medications refer to GSK1265744 or placebo.

  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • History of pancreatitis or hepatitis within the previous 6 months.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
  • Exclusion Criteria for Screening (A single repeat is allowed for eligibility determination):

Exclusion Criteria for Screening ECG:

Males Females Heart rate \<45 and >100 bpm \<50 and >100 bpm QRS duration >120 msec >120 msec (Bazett) > 450 msec > 450 msec Non-sustained (≥ 3 consecutive beats) or sustained ventricular tachycardia. Sinus Pauses >3 seconds. 2nd degree (Type II) or higher AV block. Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization)).

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    GSK1265744 30 mg

    GSK1265744 30 mg

    Drug: GSK1265744 30mg

  • Experimental
    Placebo

    Placebo to match GSK1265744

    Drug: Placebo

  • Experimental
    GSK1265744 5 mg

    GSK1265744 5 mg

    Drug: GSK1265744 5mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a lower limit of detection (LLOD) of 50 copies/milliliter (mL) (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 11

  2. GSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24])

    Blood samples for PK analysis of AUC(0-24) of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

    Time frame: Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)

  3. GSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24)

    Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

    Time frame: Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)

  4. GSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau])

    Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

    Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)

  5. GSK1265744 PK Parameters Following Dose Administration on Day 10: Predose Concentration (C0), Concentration at End of Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin)

    Blood samples for PK analysis of C0, Ctau and Cmin of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

    Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)

  6. GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Maximum Observed Concentration (Cmax)

    Blood samples for PK analysis of Cmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10

  7. GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Time to Cmax (Tmax)

    Blood samples for PK analysis of tmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10

  8. GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Terminal Half-life (t1/2) and Absorption Lag Time (Tlag)

    PK sampling was planned to be collected up to 24 hours only on Day 1 and Day 10. The data for this outcome measure was however not collected.

    Time frame: Day 1 and Day 10

  9. GSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F)

    Blood samples for PK analysis of CL/F of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

    Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)

  10. Number of Participants With Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or is associated with liver injury and impaired liver function.

    Time frame: Day 1 to Day 11

  11. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (ANC- Absolute Neutrophil Count), White Blood Cell Count

    Blood samples for assessment of hematology parameters of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC- absolute neutrophil count) and white blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  12. Change From Baseline in Hematology Parameters: Hemoglobin

    Blood samples for assessment of hematology parameter of hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  13. Change From Baseline in Hematology Parameters: Mean Corpuscle Hemoglobin

    Blood samples for assessment of hematology parameter of mean corpuscle hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  14. Change From Baseline in Hematology Parameters: Mean Corpuscle Volume

    Blood samples for assessment of hematology parameter of mean corpuscle volume was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  15. Change From Baseline in Hematology Parameters: Platelet Count

    Blood samples for assessment of hematology parameter of platelet count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  16. Change From Baseline in Hematology Parameters: Red Blood Cell Count

    Blood samples for assessment of hematology parameter of red blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  17. Change From Baseline in Hematology Parameters: Reticulocytes

    Blood samples for assessment of hematology parameter of reticulocytes was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  18. Change From Baseline in Clinical Chemistry Data: Albumin, Total Protein

    Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  19. Change From Baseline in Clinical Chemistry Data: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Lipase

    Blood samples for assessment of clinical chemistry parameters of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and lipase was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  20. Change From Baseline in Direct Bilirubin, Total Bilirubin, Calcium, Cholesterol, Creatinine, Glucose, High Density Lipoprotein (HDL) Cholesterol Direct, Low Density Lipoprotein (LDL) Cholesterol Calculation, Triglycerides, Urea/Blood Urea Nitrogen

    Blood samples for assessment of clinical chemistry parameters of direct bilirubin, total bilirubin, calcium, cholesterol, creatinine, glucose, HDL cholesterol direct, LDL cholesterol calculation, triglycerides,Urea/BUN was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  21. Change From Baseline in Clinical Chemistry Data: Chloride, Carbon Dioxide Content/Bicarbonate, Magnesium, Sodium, Potassium

    Blood samples for assessment of clinical chemistry parameters of chloride, carbon dioxide content/bicarbonate, magnesium, sodium and potassium was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 3, 7, 10

  22. Number of Participants With Urinalysis Data

    Samples for urinalysis assessment was collected on Day 1, Day 3 and Day 10. Urinalysis parameters included urine bilirubin, urine occult blood, urine glucose, urine ketones, urine nitrite, urine pH, urine protein, urine specific gravity and urine leukocyte esterase test for detecting white blood cell.

    Time frame: Day 1 to Day 10

  23. Change From Baseline in Vital Sign: Systolic and Diastolic Blood Pressure

    Systolic and diastolic blood pressure was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10

  24. Change From Baseline in Vital Sign: Heart Rate

    Heart rate was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10

  25. Change From Baseline in Electrocardiogram (ECG) Parameters

    All ECGs were obtained after a minimum 10 minute rest in a semi-supine position. The 12-lead ECGs were obtained at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10 using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and Bazett's correction (QTcB) and Fridericia correction (QTcF) intervals. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10

Secondary outcomes

  1. Change From Baseline in Plasma HIV-1 RNA

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA were collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1 pre-dose) and Day 1 (post dose), 2, 3, 4, 7, 8, 9, 10

  2. Change From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Nadir was the maximum change from Baseline in plasma HIV-1 RNA. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 11

  3. Plasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Estimated mean rate of decline (i.e., slope of day) with corresponding 90% confidence interval was provided for each treatment.

    Time frame: Up to Day 10

  4. Number of Participants With HIV-1 RNA<400 Copies/mL

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.

    Time frame: Up to Day 11

  5. Number of Participants With HIV-1 RNA<50 Copies/mL

    Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.

    Time frame: Up to Day 11

  6. Change From Baseline in CD4+ Cell Count to Day 11

    Whole venous blood samples was obtained from each participant for the analysis of lymphocyte subsets by flow cytometry on Day 1 and Day 11. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

    Time frame: Baseline (Day 1) and Day 11

  7. Pre-morning Dose Concentrations (C0) on Day 2 Through 10 to Assess the Achievement of Steady State of GSK1265744 Following Repeat Administration

    Steady state is said to be reached, when the pre-dose concentration slope estimate is close to zero. The data for pre-dose concentration on Day 1 24 hours (Day 2) through Day 10 has been presented.

    Time frame: Day 1 24 hours (Day 2), Pre-dose on Days 3, 4, 7, 8, 9 and 10

  8. Accumulation Ratios for AUC, Cmax, and Ctau

    The accumulation ratio was calculated as the ratio of AUC(0-τ), Cmax, and Ctau on Day 10 to AUC(0-24), Cmax, and C24 on Day 1 for each participant. The ratio of geometric least square means of each parameter on Day 10 to Day 1 was presented along with 90% confidence interval.

    Time frame: Days 1 and 10

  9. Day 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model

    Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (AUC\[0-24\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

    Time frame: Day 1

  10. Day 1 Cmax and C24 at Different Doses for the Assessment of Dose Proportionality Using Power Model

    Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (Cmax, and C24) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

    Time frame: Day 1

  11. Day 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model

    Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (AUC\[0-tau\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

    Time frame: Day 10

  12. Day 10 Cmax, C0 and Ctau at Different Doses for the Assessment of Dose Proportionality Using Power Model

    Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (Cmax, Ctau and C0) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

    Time frame: Day 10

07

Results

Posted Dec 6, 2017

Participant flow

This study was conducted at 4 centers in the United States from 09 June 2009 to 13 August 2009.

ITZ111451
Participant flow — ITZ111451
MilestoneGSK1265744 30 mgGSK1265744 5 mgPlaceboOptimized Therapy
Started8000
Completed7000
Not completed1000
Withdrew: Adverse event1000
ITZ112929: Randomized Regimen
Participant flow — ITZ112929: Randomized Regimen
MilestoneGSK1265744 30 mgGSK1265744 5 mgPlaceboOptimized Therapy
Started0720
Completed0720
Not completed0000
ITZ112929: Optimized Therapy (OT)
Participant flow — ITZ112929: Optimized Therapy (OT)
MilestoneGSK1265744 30 mgGSK1265744 5 mgPlaceboOptimized Therapy
Started0008
Completed0008
Not completed0000

Outcome measures

PrimaryChange From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a lower limit of detection (LLOD) of 50 copies/milliliter (mL) (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 11
Reported as:
Mean · log10 copies/mL
Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11
log10 copies/mLGSK1265744 5 mgPlacebo
Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11-2.169 ± 0.2405-0.092 ± 0.1499
Statistical analysis
  • GSK1265744 5 mg vs Placebo · ANCOVA · p = <0.001 (Analysis of covariance (ANCOVA) with treatment as fixed effect, and Baseline HIV-1 RNA as covariate.) · Mean difference (net): -2.090 · 95% CI -2.547 to -1.632
PrimaryGSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24])

Blood samples for PK analysis of AUC(0-24) of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

Time frame:
Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Reported as:
Geometric mean · Hour*microgram per milliliter (hr*µg/mL)
GSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24])
Hour*microgram per milliliter (hr*µg/mL)GSK1265744 5 mg
GSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24])7.53 ± 23
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24)

Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

Time frame:
Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Reported as:
Geometric mean · Micrograms per milliliter (µg/mL)
GSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24)
Micrograms per milliliter (µg/mL)GSK1265744 5 mg
GSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24)0.23 ± 28
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau])

Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

Time frame:
Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Reported as:
Geometric mean · hr*µg/mL
GSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau])
hr*µg/mLGSK1265744 5 mg
GSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau])17.74 ± 31
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 10: Predose Concentration (C0), Concentration at End of Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin)

Blood samples for PK analysis of C0, Ctau and Cmin of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

Time frame:
Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Reported as:
Geometric mean · µg/mL
GSK1265744 PK Parameters Following Dose Administration on Day 10: Predose Concentration (C0), Concentration at End of Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin)
µg/mLGSK1265744 5 mg
C00.54 ± 36
Ctau0.57 ± 33
Cmin0.53 ± 35
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Maximum Observed Concentration (Cmax)

Blood samples for PK analysis of Cmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10
Reported as:
Geometric mean · µg/mL
GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Maximum Observed Concentration (Cmax)
µg/mLGSK1265744 5 mg
Day 10.52 ± 20
Day 101.02 ± 25
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Time to Cmax (Tmax)

Blood samples for PK analysis of tmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10
Reported as:
Median · Hour
GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Time to Cmax (Tmax)
HourGSK1265744 5 mg
Day 12.00 (1.00 to 4.08)
Day 102.00 (1.50 to 4.08)
PrimaryGSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Terminal Half-life (t1/2) and Absorption Lag Time (Tlag)

PK sampling was planned to be collected up to 24 hours only on Day 1 and Day 10. The data for this outcome measure was however not collected.

Time frame:
Day 1 and Day 10

No measurements were reported for this outcome.

PrimaryGSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F)

Blood samples for PK analysis of CL/F of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.

Time frame:
Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Reported as:
Geometric mean · Liter per hour (L/hr)
GSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F)
Liter per hour (L/hr)GSK1265744 5 mg
GSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F)0.28 ± 31
PrimaryNumber of Participants With Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or is associated with liver injury and impaired liver function.

Time frame:
Day 1 to Day 11
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsGSK1265744 5 mgPlaceboOptimized Therapy
Any AEs023
Any SAEs000
PrimaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (ANC- Absolute Neutrophil Count), White Blood Cell Count

Blood samples for assessment of hematology parameters of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC- absolute neutrophil count) and white blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Thousand cells per microliter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (ANC- Absolute Neutrophil Count), White Blood Cell Count
Thousand cells per microliterGSK1265744 5 mgPlacebo
Basophils, Day 30.017 ± 0.02870.005 ± 0.0071
Basophils, Day 70.007 ± 0.01250.015 ± 0.0071
Basophils, Day 100.009 ± 0.01460.020 ± 0.0000
Eosinophils, Day 3-0.024 ± 0.04080.250 ± 0.4101
Eosinophils, Day 7-0.039 ± 0.04980.325 ± 0.5869
Eosinophils, Day 10-0.009 ± 0.0628-0.055 ± 0.1485
Lymphocytes, Day 30.197 ± 0.2870-0.500 ± 0.3111
Lymphocytes, Day 70.190 ± 0.2514-0.525 ± 0.1485
Lymphocytes, Day 100.229 ± 0.2738-0.720 ± 0.5515
Monocytes, Day 3-0.030 ± 0.08760.170 ± 0.2121
Monocytes, Day 7-0.039 ± 0.11260.035 ± 0.1626
Monocytes, Day 100.056 ± 0.0774-0.005 ± 0.2192
Total Neutrophils, Day 30.181 ± 0.6097-0.080 ± 0.1273
Total Neutrophils, Day 7-0.003 ± 0.6304-0.155 ± 0.2192
Total Neutrophils, Day 100.831 ± 1.60430.405 ± 1.1384
White blood cell count, Day 30.34 ± 0.282-0.15 ± 1.061
White blood cell count, Day 70.11 ± 0.782-0.30 ± 1.131
White blood cell count, Day 101.11 ± 1.508-0.35 ± 1.626
PrimaryChange From Baseline in Hematology Parameters: Hemoglobin

Blood samples for assessment of hematology parameter of hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Grams per deciliter
Change From Baseline in Hematology Parameters: Hemoglobin
Grams per deciliterGSK1265744 5 mgPlacebo
Day 30.13 ± 0.637-0.30 ± 0.424
Day 70.06 ± 0.5190.00 ± 0.424
Day 10-0.17 ± 0.446-0.15 ± 0.354
PrimaryChange From Baseline in Hematology Parameters: Mean Corpuscle Hemoglobin

Blood samples for assessment of hematology parameter of mean corpuscle hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Picogram
Change From Baseline in Hematology Parameters: Mean Corpuscle Hemoglobin
PicogramGSK1265744 5 mgPlacebo
Day 3-0.03 ± 0.1980.25 ± 0.495
Day 70.37 ± 0.4110.30 ± 0.141
Day 100.00 ± 0.3060.40 ± 0.424
PrimaryChange From Baseline in Hematology Parameters: Mean Corpuscle Volume

Blood samples for assessment of hematology parameter of mean corpuscle volume was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Femtoliter
Change From Baseline in Hematology Parameters: Mean Corpuscle Volume
FemtoliterGSK1265744 5 mgPlacebo
Day 31.0 ± 1.150.5 ± 0.71
Day 71.0 ± 1.63-0.5 ± 0.71
Day 101.7 ± 1.110.0 ± 1.41
PrimaryChange From Baseline in Hematology Parameters: Platelet Count

Blood samples for assessment of hematology parameter of platelet count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in Hematology Parameters: Platelet Count
Cells per cubic millimeterGSK1265744 5 mgPlacebo
Day 310428.6 ± 8847.925000.0 ± 21213.20
Day 715142.9 ± 29299.762500.0 ± 2121.32
Day 108000.0 ± 23860.719500.0 ± 37476.66
PrimaryChange From Baseline in Hematology Parameters: Red Blood Cell Count

Blood samples for assessment of hematology parameter of red blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Million cells per microliter
Change From Baseline in Hematology Parameters: Red Blood Cell Count
Million cells per microliterGSK1265744 5 mgPlacebo
Day 30.03 ± 0.221-0.15 ± 0.071
Day 7-0.06 ± 0.151-0.05 ± 0.071
Day 10-0.09 ± 0.135-0.10 ± 0.141
PrimaryChange From Baseline in Hematology Parameters: Reticulocytes

Blood samples for assessment of hematology parameter of reticulocytes was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Giga cells per liter
Change From Baseline in Hematology Parameters: Reticulocytes
Giga cells per literGSK1265744 5 mgPlacebo
Day 35.51 ± 9.9719.45 ± 1.768
Day 713.79 ± 27.361-6.50 ± 0.849
Day 1013.79 ± 16.41921.30 ± 35.497
PrimaryChange From Baseline in Clinical Chemistry Data: Albumin, Total Protein

Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Grams per deciliter
Change From Baseline in Clinical Chemistry Data: Albumin, Total Protein
Grams per deciliterGSK1265744 5 mgPlacebo
Albumin, Day 30.16 ± 0.1620.00 ± 0.000
Albumin, Day 70.08 ± 0.1170.05 ± 0.071
Albumin, Day 100.06 ± 0.0980.15 ± 0.071
Total protein, Day 30.24 ± 0.4470.05 ± 0.212
Total protein, Day 70.03 ± 0.2940.10 ± 0.424
Total protein, Day 10-0.10 ± 0.3420.10 ± 0.000
PrimaryChange From Baseline in Clinical Chemistry Data: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Lipase

Blood samples for assessment of clinical chemistry parameters of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and lipase was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Units per liter
Change From Baseline in Clinical Chemistry Data: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Lipase
Units per literGSK1265744 5 mgPlacebo
Alkaline phosphatase, Day 31.6 ± 3.10-3.5 ± 4.95
Alkaline phosphatase, Day 70.5 ± 3.89-5.0 ± 0.00
Alkaline phosphatase, Day 10-2.4 ± 6.55-4.0 ± 2.83
Alanine amino transferase, Day 32.9 ± 6.41-4.0 ± 2.83
Alanine amino transferase, Day 7-0.2 ± 4.02-1.5 ± 9.19
Alanine amino transferase, Day 102.0 ± 4.12-2.5 ± 7.78
Aspartate amino transferase, Day 3-1.0 ± 4.28-2.0 ± 8.49
Aspartate amino transferase, Day 7-1.0 ± 3.52-3.5 ± 7.78
Aspartate amino transferase, Day 100.4 ± 5.32-2.0 ± 5.66
Creatine kinase, Day 3-0.1 ± 11.42-29.5 ± 10.61
Creatine kinase, Day 727.7 ± 77.11-48.0 ± 42.43
Creatine kinase, Day 1020.6 ± 42.97-40.5 ± 43.13
Lipase, Day 30.9 ± 8.914.0 ± 2.83
Lipase, Day 7-0.9 ± 17.22-1.0 ± 8.49
Lipase, Day 100.3 ± 14.42-2.0 ± 2.83
PrimaryChange From Baseline in Direct Bilirubin, Total Bilirubin, Calcium, Cholesterol, Creatinine, Glucose, High Density Lipoprotein (HDL) Cholesterol Direct, Low Density Lipoprotein (LDL) Cholesterol Calculation, Triglycerides, Urea/Blood Urea Nitrogen

Blood samples for assessment of clinical chemistry parameters of direct bilirubin, total bilirubin, calcium, cholesterol, creatinine, glucose, HDL cholesterol direct, LDL cholesterol calculation, triglycerides,Urea/BUN was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Milligrams per deciliter
Change From Baseline in Direct Bilirubin, Total Bilirubin, Calcium, Cholesterol, Creatinine, Glucose, High Density Lipoprotein (HDL) Cholesterol Direct, Low Density Lipoprotein (LDL) Cholesterol Calculation, Triglycerides, Urea/Blood Urea Nitrogen
Milligrams per deciliterGSK1265744 5 mgPlacebo
Direct bilirubin, Day 3-0.04 ± 0.113-0.05 ± 0.071
Direct bilirubin, Day 7-0.10 ± 0.126-0.05 ± 0.071
Direct bilirubin, Day 10-0.06 ± 0.0530.00 ± 0.000
Total bilirubin, Day 3-0.06 ± 0.207-0.25 ± 0.354
Total bilirubin, Day 7-0.03 ± 0.186-0.40 ± 0.566
Total bilirubin, Day 100.00 ± 0.216-0.10 ± 0.141
Calcium, Day 30.13 ± 0.1980.00 ± 0.141
Calcium, Day 70.17 ± 0.2070.05 ± 0.495
Calcium, Day 10-0.09 ± 0.2540.20 ± 0.000
Cholesterol, Day 35.7 ± 8.90-7.5 ± 9.19
Cholesterol, Day 716.2 ± 32.600.0 ± 1.41
Cholesterol, Day 104.0 ± 13.171.0 ± 2.83
Creatinine, Day 30.03 ± 0.0490.05 ± 0.071
Creatinine, Day 70.05 ± 0.1050.05 ± 0.071
Creatinine, Day 100.03 ± 0.0760.05 ± 0.071
Glucose, Day 316.1 ± 28.352.0 ± 1.41
Glucose, Day 7-16.5 ± 45.624.5 ± 3.54
Glucose, Day 100.1 ± 5.81-4.0 ± 0.00
HDL cholesterol, direct, Day 3-0.6 ± 2.44-1.5 ± 2.12
HDL cholesterol, direct, Day 7-0.2 ± 9.620.5 ± 0.71
HDL cholesterol, direct, Day 101.9 ± 4.56-2.0 ± 1.41
LDL cholesterol calculation, Day 36.7 ± 9.21-7.0 ± 12.73
LDL cholesterol calculation, Day 7-0.2 ± 9.933.5 ± 6.36
LDL cholesterol calculation, Day 101.6 ± 10.42-2.5 ± 16.26
Triglycerides, Day 3-1.9 ± 49.695.0 ± 4.24
Triglycerides, Day 7258.3 ± 636.46-20.5 ± 21.92
Triglycerides, Day 103.6 ± 39.5928.5 ± 72.83
Urea/BUN, Day 31.4 ± 2.15-1.0 ± 5.66
Urea/BUN, Day 71.3 ± 3.27-2.5 ± 4.95
Urea/BUN, Day 100.7 ± 2.81-2.0 ± 0.00
PrimaryChange From Baseline in Clinical Chemistry Data: Chloride, Carbon Dioxide Content/Bicarbonate, Magnesium, Sodium, Potassium

Blood samples for assessment of clinical chemistry parameters of chloride, carbon dioxide content/bicarbonate, magnesium, sodium and potassium was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 3, 7, 10
Reported as:
Mean · Milliequivalents per liter
Change From Baseline in Clinical Chemistry Data: Chloride, Carbon Dioxide Content/Bicarbonate, Magnesium, Sodium, Potassium
Milliequivalents per literGSK1265744 5 mgPlacebo
Chloride, Day 30.0 ± 0.822.0 ± 0.00
Chloride, Day 7-0.2 ± 2.792.0 ± 0.00
Chloride, Day 10-0.7 ± 2.692.0 ± 4.24
Carbon dioxide content/Bicarbonate, Day 3-0.9 ± 2.41-1.0 ± 0.00
Carbon dioxide content/Bicarbonate, Day 7-1.3 ± 1.63-2.0 ± 2.83
Carbon dioxide content/Bicarbonate, Day 100.6 ± 2.76-2.0 ± 2.83
Potassium, Day 30.20 ± 0.2000.30 ± 0.141
Potassium, Day 70.00 ± 0.2450.20 ± 0.283
Potassium, Day 100.07 ± 0.3680.05 ± 0.212
Magnesium, Day 3-0.04 ± 0.0980.10 ± 0.000
Magnesium, Day 7-0.00 ± 0.0890.10 ± 0.141
Magnesium, Day 10-0.04 ± 0.0980.00 ± 0.141
Sodium, Day 3-0.4 ± 1.620.5 ± 0.71
Sodium, Day 70.3 ± 2.500.5 ± 0.71
Sodium, Day 10-0.4 ± 1.620.5 ± 2.12
PrimaryNumber of Participants With Urinalysis Data

Samples for urinalysis assessment was collected on Day 1, Day 3 and Day 10. Urinalysis parameters included urine bilirubin, urine occult blood, urine glucose, urine ketones, urine nitrite, urine pH, urine protein, urine specific gravity and urine leukocyte esterase test for detecting white blood cell.

Time frame:
Day 1 to Day 10
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Data
ParticipantsGSK1265744 5 mgPlacebo
Day 1, Urine Bilirubin, Negative72
Day 1, Urine Occult Blood, Negative72
Day 1, Urine Glucose, Negative72
Day 1, Urine Ketones, Negative72
Day 1, Urine Nitrite, Negative62
Day 1, Urine Nitrite, Positive10
Day 1, Urine pH, 5.521
Day 1, Urine pH, 641
Day 1, Urine pH, 6.510
Day 1, Urine Protein, Negative72
Day 1, Urine Specific Gravity, 1.00610
Day 1, Urine Specific Gravity, 1.01401
Day 1, Urine Specific Gravity, 1.01501
Day 1, Urine Specific Gravity, 1.01710
Day 1, Urine Specific Gravity, 1.01920
Day 1, Urine Specific Gravity, 1.02110
Day 1, Urine Specific Gravity, 1.02510
Day 1, Urine Specific Gravity, 1.0310
Day 1, ULET for white blood cell, Negative72
Day 3, Urine Bilirubin, Negative72
Day 3, Urine Occult Blood, Negative62
Day 3, Urine Occult Blood, 1+10
Day 3, Urine Glucose, 3+10
Day 3, Urine Glucose, Negative62
Day 3, Urine Ketones, Negative72
Day 3, Urine Nitrite, Negative62
Day 3, Urine Nitrite, Positive10
Day 3, Urine pH, 5.541
Day 3, Urine pH, 621
Day 3, Urine pH, 6.510
Day 3, Urine Protein, Negative62
Day 3, Urine Protein, Trace10
Day 3, Urine Specific Gravity, 1.01610
Day 3, Urine Specific Gravity, 1.01711
Day 3, Urine Specific Gravity, 1.01801
Day 3, Urine Specific Gravity, 1.02120
Day 3, Urine Specific Gravity, 1.02210
Day 3, Urine Specific Gravity, 1.02710
Day 3, Urine Specific Gravity, 1.0310
Day 3, ULET for white blood cell, 2+10
Day 3, ULET for white blood cell, Negative62
Day 10, Urine Bilirubin, Negative72
Day 10, Urine Occult Blood, 2+10
Day 10, Urine Occult Blood, Negative62
Day 10, Urine Glucose, Negative72
Day 10, Urine Ketones, Negative72
Day 10, Urine Nitrite, Negative62
Day 10, Urine Nitrite, Positive10
Day 10, Urine pH, 5.501
Day 10, Urine pH, 641
Day 10, Urine pH, 6.530
Day 10, Urine Protein, Negative52
Day 10, Urine Protein, Trace20
Day 10, Urine Specific Gravity, 1.00901
Day 10, Urine Specific Gravity, 1.01601
Day 10, Urine Specific Gravity, 1.0210
Day 10, Urine Specific Gravity, 1.02110
Day 10, Urine Specific Gravity, 1.02310
Day 10, Urine Specific Gravity, 1.02520
Day 10, Urine Specific Gravity, 1.02710
Day 10, Urine Specific Gravity, 1.0310
Day 10, ULET for white blood cell, Negative72
PrimaryChange From Baseline in Vital Sign: Systolic and Diastolic Blood Pressure

Systolic and diastolic blood pressure was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Vital Sign: Systolic and Diastolic Blood Pressure
Millimeters of mercury (mmHg)GSK1265744 5 mgPlacebo
Systolic blood pressure, Day 1, 2 Hours1.2 ± 8.595.8 ± 0.35
Systolic blood pressure, Day 4, Pre dose1.8 ± 9.165.8 ± 3.18
Systolic blood pressure, Day 7, Pre dose-2.5 ± 11.22-4.3 ± 8.84
Systolic blood pressure, Day 10, Pre dose0.6 ± 19.1919.8 ± 14.50
Systolic blood pressure, Day 10, 2 Hours-0.2 ± 10.5913.3 ± 4.60
Diastolic blood pressure, Day 1, 2 Hours-5.7 ± 5.76-0.5 ± 2.12
Diastolic blood pressure, Day 4, Pre dose-2.4 ± 8.91-2.5 ± 10.61
Diastolic blood pressure, Day 7, Pre dose-1.6 ± 9.28-5.0 ± 15.56
Diastolic blood pressure, Day 10, Pre dose-5.4 ± 13.858.5 ± 14.85
Diastolic blood pressure, Day 10, 2 Hours-2.4 ± 6.826.5 ± 9.19
PrimaryChange From Baseline in Vital Sign: Heart Rate

Heart rate was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign: Heart Rate
Beats per minuteGSK1265744 5 mgPlacebo
Day 1, 2 Hours-7.0 ± 2.10-5.8 ± 4.60
Day 4, Pre dose5.3 ± 6.24-5.8 ± 1.06
Day 7, Pre dose6.3 ± 5.71-1.8 ± 1.77
Day 10, Pre dose0.0 ± 6.745.8 ± 4.60
Day 10, 2 Hours-7.6 ± 5.12-10.8 ± 3.18
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters

All ECGs were obtained after a minimum 10 minute rest in a semi-supine position. The 12-lead ECGs were obtained at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10 using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and Bazett's correction (QTcB) and Fridericia correction (QTcF) intervals. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Reported as:
Mean · Milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters
Milliseconds (msec)GSK1265744 5 mgPlacebo
PR, Day 1, 2 Hours0.0 ± 1.831.0 ± 2.83
PR, Day 4, Pre dose4.0 ± 5.425.0 ± 11.31
PR, Day 7, Pre dose-0.9 ± 4.670.0 ± 12.73
PR, Day 10, Pre dose-1.7 ± 3.040.0 ± 9.90
PR, Day 10, 2 Hours4.3 ± 10.094.0 ± 12.73
QRS, Day 1, 2 Hours-0.7 ± 3.681.5 ± 0.71
QRS, Day 4, Pre dose0.7 ± 2.36-3.5 ± 12.02
QRS, Day 7, Pre dose-0.1 ± 4.263.5 ± 2.12
QRS, Day 10, Pre dose1.0 ± 5.070.5 ± 3.54
QRS, Day 10, 2 Hours-0.7 ± 8.995.5 ± 4.95
QT, Day 1, 2 Hours18.1 ± 8.0727.0 ± 24.04
QT, Day 4, Pre dose-10.7 ± 20.935.0 ± 7.07
QT, Day 7, Pre dose-13.6 ± 13.1311.0 ± 1.41
QT, Day 10, Pre dose-3.3 ± 14.14-11.0 ± 24.04
QT, Day 10, 2 Hours19.0 ± 22.1525.0 ± 24.04
QTcB, Day 1, 2 Hours0.2 ± 13.506.0 ± 4.09
QTcB, Day 4, Pre dose2.0 ± 16.15-17.9 ± 2.20
QTcB, Day 7, Pre dose-0.0 ± 16.95-9.0 ± 25.73
QTcB, Day 10, Pre dose1.4 ± 16.59-15.6 ± 10.35
QTcB, Day 10, 2 Hours-2.4 ± 12.35-18.1 ± 0.42
QTcF, Day 1, 2 Hours6.4 ± 11.4513.3 ± 11.06
QTcF, Day 4, Pre dose-2.4 ± 14.27-10.0 ± 4.05
QTcF, Day 7, Pre dose-4.7 ± 13.05-2.0 ± 16.30
QTcF, Day 10, Pre dose-0.2 ± 13.17-13.9 ± 15.19
QTcF, Day 10, 2 Hours4.9 ± 13.62-3.4 ± 7.99
SecondaryChange From Baseline in Plasma HIV-1 RNA

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA were collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1 pre-dose) and Day 1 (post dose), 2, 3, 4, 7, 8, 9, 10
Reported as:
Mean · Log10 copies/mL
Change From Baseline in Plasma HIV-1 RNA
Log10 copies/mLGSK1265744 5 mgPlacebo
Day 10.000 ± 0.00000.000 ± NA
Day 2-0.126 ± 0.22550.058 ± 0.2303
Day 3-0.618 ± 0.1341-0.299 ± 0.2737
Day 4-0.830 ± 0.2424-0.146 ± 0.0580
Day 7-1.577 ± 0.5498-0.168 ± 0.1264
Day 8-1.935 ± 0.4717-0.146 ± 0.2779
Day 9-2.013 ± 0.4192-0.007 ± 0.1960
Day 10-2.160 ± 0.2810-0.158 ± 0.1930
SecondaryChange From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Nadir was the maximum change from Baseline in plasma HIV-1 RNA. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 11
Reported as:
Mean · log10 copies/mL
Change From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days
log10 copies/mLGSK1265744 5 mgPlacebo
Change From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days-2.199 ± 0.2491-0.418 ± 0.1058
Statistical analysis
  • GSK1265744 5 mg vs Placebo · ANCOVA · p = <0.001 (ANCOVA with treatment as fixed effect, and baseline HIV-1 RNA as covariate.) · Mean difference (net): -1.804 · 95% CI -2.173 to -1.436
SecondaryPlasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Estimated mean rate of decline (i.e., slope of day) with corresponding 90% confidence interval was provided for each treatment.

Time frame:
Up to Day 10
Reported as:
Mean · log10 copies per mL per day
Plasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days
log10 copies per mL per dayGSK1265744 5 mgPlacebo
Plasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days-0.2313 (-0.2513 to -0.2113)0.0013 (-0.0233 to 0.0259)
Statistical analysis
  • GSK1265744 5 mg vs Placebo · ANCOVA · p = <0.0001
SecondaryNumber of Participants With HIV-1 RNA<400 Copies/mL

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.

Time frame:
Up to Day 11
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 RNA<400 Copies/mL
ParticipantsGSK1265744 5 mgPlacebo
Day 720
Day 840
Day 940
Day 1050
Day 1150
SecondaryNumber of Participants With HIV-1 RNA<50 Copies/mL

Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.

Time frame:
Up to Day 11
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 RNA<50 Copies/mL
ParticipantsGSK1265744 5 mgPlacebo
Day 820
Day 930
Day 1020
Day 1120
SecondaryChange From Baseline in CD4+ Cell Count to Day 11

Whole venous blood samples was obtained from each participant for the analysis of lymphocyte subsets by flow cytometry on Day 1 and Day 11. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.

Time frame:
Baseline (Day 1) and Day 11
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+ Cell Count to Day 11
Cells per cubic millimeterGSK1265744 5 mgPlacebo
Change From Baseline in CD4+ Cell Count to Day 1171.0 ± 56.62-84.0 ± 145.66
SecondaryPre-morning Dose Concentrations (C0) on Day 2 Through 10 to Assess the Achievement of Steady State of GSK1265744 Following Repeat Administration

Steady state is said to be reached, when the pre-dose concentration slope estimate is close to zero. The data for pre-dose concentration on Day 1 24 hours (Day 2) through Day 10 has been presented.

Time frame:
Day 1 24 hours (Day 2), Pre-dose on Days 3, 4, 7, 8, 9 and 10
Reported as:
Mean · µg/mL
Pre-morning Dose Concentrations (C0) on Day 2 Through 10 to Assess the Achievement of Steady State of GSK1265744 Following Repeat Administration
µg/mLGSK1265744 5 mg
DAY 1, 24 hours (Day 2)0.2363 ± 0.06884
DAY 3, Pre-dose0.3539 ± 0.12999
DAY 4, Pre-dose0.4128 ± 0.15566
DAY 7, Pre-dose0.5239 ± 0.11899
DAY 8, Pre-dose0.5744 ± 0.17622
DAY 9, Pre-dose0.5688 ± 0.16880
DAY 10, Pre-dose0.5654 ± 0.20609
SecondaryAccumulation Ratios for AUC, Cmax, and Ctau

The accumulation ratio was calculated as the ratio of AUC(0-τ), Cmax, and Ctau on Day 10 to AUC(0-24), Cmax, and C24 on Day 1 for each participant. The ratio of geometric least square means of each parameter on Day 10 to Day 1 was presented along with 90% confidence interval.

Time frame:
Days 1 and 10
Reported as:
Geometric least squares mean · Ratio
Accumulation Ratios for AUC, Cmax, and Ctau
RatioGSK1265744 5 mg
Accumulation Ratio AUC2.355 (2.086 to 2.658)
Accumulation Ratio Cmax1.961 (1.684 to 2.283)
Accumulation Ratio Ctau2.483 (2.141 to 2.880)
SecondaryDay 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model

Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (AUC\[0-24\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

Time frame:
Day 1
Reported as:
Mean · hr*µg/mL/mg
Day 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model
hr*µg/mL/mgPooled GSK1265744
Day 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model0.952 (0.802 to 1.101)
SecondaryDay 1 Cmax and C24 at Different Doses for the Assessment of Dose Proportionality Using Power Model

Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (Cmax, and C24) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

Time frame:
Day 1
Reported as:
Mean · μg/mL/mg
Day 1 Cmax and C24 at Different Doses for the Assessment of Dose Proportionality Using Power Model
μg/mL/mgPooled GSK1265744
Cmax0.950 (0.812 to 1.088)
C240.949 (0.777 to 1.121)
SecondaryDay 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model

Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (AUC\[0-tau\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

Time frame:
Day 10
Reported as:
Mean · hr*µg/mL/mg
Day 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model
hr*µg/mL/mgPooled GSK1265744
Day 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model0.988 (0.841 to 1.135)
SecondaryDay 10 Cmax, C0 and Ctau at Different Doses for the Assessment of Dose Proportionality Using Power Model

Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (Cmax, Ctau and C0) using the power model. The mean slope and corresponding 90% confidence interval has been presented.

Time frame:
Day 10
Reported as:
Mean · µg/mL/mg
Day 10 Cmax, C0 and Ctau at Different Doses for the Assessment of Dose Proportionality Using Power Model
µg/mL/mgPooled GSK1265744
Cmax1.025 (0.903 to 1.147)
C00.936 (0.761 to 1.110)
Ctau0.980 (0.808 to 1.151)

Adverse events

Collected over Up to follow-up visit (Day 25±1). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1265744 30 mg0/8 (0%)0/8 (0%)4/8 (50%)
GSK1265744 5 mg0/7 (0%)0/7 (0%)0/7 (0%)
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Optimized Therapy0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGSK1265744 30 mgGSK1265744 5 mgPlaceboOptimized Therapy
NauseaGastrointestinal disorders0/80/71/21/8
Blood bilirubin increasedInvestigations0/80/71/21/8
Pain in extremityMusculoskeletal and connective tissue disorders0/80/71/20/8
DizzinessNervous system disorders3/80/70/20/8
HeadacheNervous system disorders2/80/70/21/8
DyspepsiaGastrointestinal disorders2/80/70/20/8
Abdominal painGastrointestinal disorders0/80/70/21/8
ConstipationGastrointestinal disorders0/80/70/21/8
Ocular icterusEye disorders0/80/70/21/8
SomnolenceNervous system disorders1/80/70/20/8

Baseline characteristics

Age, Customized
Age, Customized(Participants)GSK1265744 30 mgGSK1265744 5 mgPlaceboTotal
27 to 51 Years87217
Sex: Female, Male
Sex: Female, Male(Participants)GSK1265744 30 mgGSK1265744 5 mgPlaceboTotal
Female0202
Male85215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GSK1265744 30 mgGSK1265744 5 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0202
White85215
More than one race0000
Unknown or Not Reported0000
08

Study locations

4 sites
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2009 to primary completion in Aug 2009, 2 months.

Results were first posted in Dec 2017, 8 years 3 months after primary completion. A results delay was requested in Aug 2010.

Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 2 months is below that.

Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2009
First posted
Jun 15, 2009
StartActual
Jun 9, 2009
Primary completionActual
Aug 13, 2009
CompletionActual
Aug 13, 2009
Results delay requested
Aug 12, 2010
Results first posted
Dec 6, 2017
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00920426
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 15, 2009
Start date
Jun 9, 2009
Primary completion
Aug 13, 2009
Completion
Aug 13, 2009
Results posted
Dec 6, 2017
Last update
Dec 6, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion